World Health Organization Sounds Alert Over Severe Scarcity of Obesity Jabs

Less than 10% of patients who could benefit from obesity jabs including Wegovy can access them, caution the global health agency as it publishes its first advice on the drugs.

Considering over a billion individuals worldwide now living with obesity, it is calling for increased and just access to this class of drugs.

Per forecasts, more than two billion will be living with obesity by 2030 if no action is taken.

"Our new guidance affirms that obesity is a lifelong illness that can be treated with holistic and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and logistical bottlenecks are significant hurdles to widespread availability to the jabs that can assist patients in reducing significant weight, notes the organization.

Skinny Jab Scarcity

Even in the present best projected outlook, the supply of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of the global need, per the health organization.

The guideline urges governments and firms to increase access, by strategies such as licensing agreements.

A patent on a key compound – the core component of a leading brand – is due to expire in a number of nations in 2026.

The Way Weight-Loss Injections Operate

These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so people reduce food intake.

Individuals usually see weight reduction after several weeks of commencing the regular doses.

Research points to patients may regain a significant portion after a year of halting the medication, because their usual appetite resume.

To be carrying excess weight elevates your risk for contracting medical conditions, including diabetes, cardiovascular issues, brain attack, and specific cancers.

Obesity affects people in all nations and was associated with millions of deaths worldwide in 2024, according to the health agency.